Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Pfizer (PFE) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Pfizer (PFE) lobbying for?
Summary of the Lobbying Data:
For the past ten contracts submitted, Pfizer has hired multiple lobbying firms that include Subject Matter (Fka Elmendorf Ryan), Pllc, Llp, Cornerstone Government Affairs, Inc., Pfizer Inc., The Duberstein Group Inc., Thegroup Dc, Llc, Akin Gump Strauss Hauer & Feld, Federal Health Policy Strategies, Hardy & Bacon, Nvg, Shook, Williams And Jensen. The company lobbied on various general issues, including Taxation/Internal Revenue Code, Defense, Health Issues, Law Enforcement/Crime/Criminal Justice, Medicare/Medicaid, Copyright/Patent/Trademark, Trade (domestic/foreign), and Budget/Appropriations. Pfizer also lobbied on specific issues such as drug pricing, intellectual property, global supply chains, and access to COVID-19 therapy.
The company targeted various government agencies, including the Department of State (DOS), Office of Management & Budget (OMB), Centers For Disease Control & Prevention (CDC), House of Representatives, Office of the Vice President of the United States, Department of Treasury, Food & Drug Administration (FDA), White House Office, National Economic Council (NEC), Department of Health & Human Services (HHS), Senate, U.S. Trade Representative (USTR), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), and Department of Commerce (DOC).
One could infer that Pfizer is lobbying on these issues to ensure regulatory policies, taxes, and laws that favor its business operations. The issues that Pfizer is lobbying on may affect the cost of its products, access to markets, and other factors that could affect its revenues. Therefore, lobbying on these issues is a way for Pfizer to influence regulatory and legislative outcomes that align with its corporate interests. For example, lobbying on COVID-19 therapy access and supply chain issues could be interpreted as Pfizer’s attempt to position itself as a key player in the pandemic response and to ensure that its products remain in high demand.
